Catabasis Pharmaceuticals to Present Pre-Clinical Data Supporting CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week 2016

CAMBRIDGE, MA, May 16, 2016 – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that pre-clinical data will be presented that supports CAT-2054 as a potential treatment for NASH at Digestive Disease Week 2016 held May 21 - 24, 2016, in San Diego, California at the San Diego Convention Center. The data that will be presented was generated using CAT-2003, an analog of CAT-2054, to demonstrate the potential of CAT-2054 in NASH. CAT-2054 is currently in a Phase 2a clinical trial in patients with hypercholesterolemia.

Dominic Picarella, Ph.D., Director of Pharmacology, will present a poster titled “CAT-2003, an Analog of CAT-2054, a Novel Oral Sterol Regulatory Element Binding Protein Inhibitor, Inhibits Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis (NASH).” The poster session will take place on Saturday, May 21, 2016 from 9:30 a.m. to 4:00 p.m. local time.

About CAT-2054
CAT-2054 is an oral small molecule with a novel mechanism of action being developed as a potential treatment of nonalcoholic steatohepatitis (NASH) and hypercholesterolemia. By inhibiting Sterol Regulatory Element-Binding Protein (SREBP), a master regulator of lipid metabolism in the body, CAT-2054 has the potential to significantly reduce LDL-C and liver fat; it may also have beneficial effects on other metabolic parameters such as triglycerides and glucose. This profile may differentiate CAT-2054 from currently approved therapies and others in development. We have shown in pre-clinical models of NASH that the CAT-2000 series significantly improves liver inflammation, fibrosis and steatosis. We have previously reported positive top-line Phase 1 data, including reductions in LDL-C. We are currently conducting a Phase 2a trial of CAT-2054 in addition to high intensity statin therapy in patients with hypercholesterolemia, which may help guide future clinical trials in NASH and hypercholesterolemia.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. We have product candidates in both rare diseases and serious lipid disorders. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare
diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit [www.catabasis.com](http://www.catabasis.com).

**About Digestive Disease Week® (DDW)**

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW take place May 21-24, 2016, at the San Diego Convention Center, San Diego, CA. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at [www.ddw.org](http://www.ddw.org).

###

**Corporate and Media Contact**

Andrea Matthews  
Catabasis Pharmaceuticals, Inc.  
T: (617) 349-1971  
[amatthews@catabasis.com](mailto:amatthews@catabasis.com)